

Why Did Pfizer Refuse to Distribute the Vaccine in Countries Which Didn't Grant Indemnity?

By Will Jones

Global Research, December 12, 2021

Before It's News 10 December 2021

Theme: Intelligence, Science and Medicine

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), click here.

Visit and follow us on Instagram at @crg_globalresearch.

A video has <u>surfaced</u> from what appears to be January 2021 of World Bank President David Malpass explaining that Pfizer is "hesitant" to distribute its vaccine in countries which refuse to grant legal indemnity from liability for adverse events. He says:

The immediate problem is indemnification. Pfizer has been hesitant to go into some of the countries because of the liability problems, they don't have a liability shield. So we work with the countries to try to do that. But I think also some of the other vaccine manufacturers may be able to go into countries because they're operating through subsidiaries. This is all something that we're exploring, and our goal, my goal, is to have vaccines available throughout the developing world based on what their countries decide. We've got financing available but the countries need to choose systems and then begin buying or receiving the vaccines.

"Pfizer has been hesitant to go into some of the countries because of the liability problems, they don't have a liability shield" - World Bank President David Malpass <u>pic.twitter.com/Ze49ylDejP</u>

— Belvoir (@BelvoirPLC) <u>December 3, 2021</u>

If Pfizer is so confident that its vaccine has been proven safe in rigorous trials, why is it unwilling to take responsibility for any problems?

And if it is unwilling to take the risk with its own product, how is that going to persuade the vaccine-hesitant to take the risk themselves?

The Pfizer vaccine has been <u>linked</u> with 388,618 adverse events in the UK to date, including 628 deaths.

Taiwan has <u>halted</u> its use in teenagers due to concerns about the risk of myocarditis.

Yet a <u>cloak of secrecy</u> has been thrown over the approvals process and the company has <u>come under fire</u> for "war profiteering" by making huge profits during the pandemic.

Pharmaceutical companies are profit-driven entities and rules on transparency and liability exist to keep them honest and ensure only safe, effective drugs are provided to the public. It may turn out to be a big mistake to have allowed them to avoid this scrutiny and accountability just because many were desperate for a medical way out of the pandemic.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums, etc.

Featured image is from Before It's News

The original source of this article is <u>Before It's News</u> Copyright © <u>Will Jones</u>, <u>Before It's News</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Will Jones

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca